Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL GENITAL HERPES TREATMENT MARKET WAS VALUED AT USD 2.3 BILLION IN 2021 AND IS EXPECTED TO REACH USD 2.9 BILLION BY 2027, GROWING AT A CAGR OF AROUND 3.76%.
The Global Genital Herpes Treatment Market Size, Share, Trends Analysis
- Drug Type: Acyclovir, Valacyclovir, Famciclovir, and Other Drugs
- Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies
- Virus Type: HSV-2 and HSV-1
- Route Of Administration: Oral, Topical, and Injection
- Region: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
GLOBAL GENITAL HERPES TREATMENT MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2027) | USD 2.3 Billion |
| Market Size (2021) | USD 2.9 Billion |
| CAGR (2022-2027) | 3.76% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Drug Type, Distribution Channel, Virus TypeRoute Of Administration, and Region |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | GlaxoSmithKline, Glenmark pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, and Bausch Health Companies |
The global genital herpes treatment market was valued at around USD 2.3 billion in 2021 and is expected to reach approximately USD 2.9 billion by 2027, growing at a CAGR of about 3.76%. Herpes simplex virus (HSV), also known as herpes, is a widespread infection worldwide. HSV-1 causes infection in or around the mouth (oral herpes), but it can also cause genital herpes. Herpes simplex virus type 2 (HSV-2) causes genital herpes, a dangerous sexually transmitted infection (STI). The genitals of those who have genital herpes develop painful blisters. Blisters can form on the anus or inside it. Oral and vaginal herpes is usually asymptomatic or unnoticed, but they can cause painful blisters or ulcers at the injection site, ranging from mild to severe. The infection is permanent, and symptoms might repeat for years.
The World Health Organization estimates that 20% of people living with HIV / AIDS are in their 20s and that 1 in 20 adolescents get STI each year. Adolescents are more likely to engage in unprotected sex, have multiple sexual partners, and engage in transgenerational transactional sex. The cervical lining in female adults and young women makes them more susceptible to STIs. According to the CDC, roughly 20% of the U.S. population - approximately one out of every five people in the U.S. had an STI on any given day in 2018; October 13 is National Herpes Awareness Day, an excellent opportunity to raise awareness about the causes and treatment of various types of herpes contaminations, particularly genital herpes. The disease and treatment searches are increasing with the high internet penetration around the globe. Young adults are giving more time to internet browsing. They frequently search about the treatment methods for STIs and their prevention. MSM are vulnerable demographics to spreading STIs. While anyone who has sex can get an STD, the sexually active LGBT population, including gay, bisexual, and MSM, are at greater risk. In addition to getting higher rates of HSV, more than half of all new HIV infections happen among MSM. Many aspects contribute to the higher rates of STIs among LGBT.
Promising Investigational Therapies for Treating Genital Herpes
- Researchers have been working on the development of herpes vaccines for decades. Several clinical trials have been conducted to test therapeutic (to reduce recurrence and viral shedding in people already infected with HSV) and prophylactic (to prevent infection) drug candidates.
- mRNA-1608 a Moderna's HSV, is a vaccine candidate against HSV-2 infection. Moderna believes that an HSV-2 vaccine could provide cross-protection against HSV-1. With mRNA-1608, the Company intends to bring a strong antibody reaction with neutralizing and effector functionality shared with cell-mediated immunity.
- HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and other critical Genital Herpes pipeline medicines are in various stages of clinical trials for the treatment of Genital Herpes.
- Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg ImmunoTherapeutics, AiCuris, and United Biopharma are some of the most well-known pharmaceutical companies active in the field.
- X-Vax Technology announced in May 2021 that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental herpes simplex virus 1 and 2 vaccines (HSV-1 and -2).
- The FDA granted AiCuris Breakthrough Therapy Designation for Pritelivir to treat HSV infections in immunocompromised patients in June 2020.
Increasing Demand for Genital Herpes Treatment by Homosexuals
- Homosexual acceptance increased by double digits between 2002 and 2019. This includes a 21-point increase in South Africa since 2002 and a 19-point increase in South Korea over the same period. India has also seen a rise of 22 points since 2014.
- MSM groups are at increased risk of HIV and other STIs due to sexual networks, the number of concurrent partners, and behavioral or biological factors such as condom-less sex, anal sex, drug use, etc.
- MSM are vulnerable demographics to spreading STIs. While anyone having sex can get an STD, the sexually active LGBT population, including gay, bisexual, and MSM, are at greater risk.
- In addition to getting higher rates of HSV, more than half of all new HIV infections happen among MSM. Many aspects contribute to the higher rates of STIs among MSM.
Growing Burden of Sexually Transmitted Diseases
- As the latest data from WHO, an expected 3.7 billion individuals younger than 50, or 67% of the populace, in 2016 had HSV-1 contamination (oral or genital). The assessed predominance of the contamination was most elevated in Africa (88%) and least in the Americas (45%).
- Genital herpes caused by HSV-2 is a global problem. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years suffered from infections worldwide in 2016. More women than men are infected with HSV-2. In 2016, an estimated 313 million women and 178 million men lived with the infection. This is because male-to-female sexually transmitted HSV is more efficient than female-to-male sexual transmission.
- Genital herpes is a worldwide issue, and an expected 491 million (around 13%) individuals between 15 and 49 years suffer from this STD. In 2016, around 313 million women and 178 million men had genital herpes. This is because sexual transmission of HSV is more proficient from men to ladies than from ladies to men. The pervasiveness of HSV-2 disease was assessed to be most noteworthy in Africa (44% in ladies and 25% in men), trailed by the Americas (24% in ladies and 12% in men).
MARKET SEGMENTATION ANALYSIS
The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
The Acyclovir segment reported a significant share of around 50.44% among all drug types. The Acyclovir is the leading segment due to availability in all three major routes of administration. The key player in the genital herpes treatment GSK has the branded drug Zovirax. Acyclovir is the oldest drug in the antiviral category and has many generic versions of Zovirax available on the market.
The Retail pharmacies segment reported a significant share of around 49.79% among all distribution channels. The retail pharmacy segment is showing the highest share due to the availability of branded and generic versions of all antiviral drugs in retail pharmacies. People who have genital herpes is most referred to go to nearby retail pharmacy outlet for anti-genital herpes treatment because of the stigma related to sexually transmitted diseases.
The HSV-2 segment reported a major share of around 84.10% among all virus types. HSV-2 is the leading virus type segment, as HSV-2 is the leading cause of genital herpes. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years were suffering from infections worldwide in 2016. More women than men are infected with HSV-2.
Among all routes of administration, the oral segment reported a major share of around 64.03%. Mostly all the anti-genital herpes drugs are available in an oral formulation. Chronic suppressive doses of oral antivirals, including Acyclovir (Zovirax), valacyclovir (Valtrex), and famciclovir, have significantly reduced the incidence of clinical recurrence and the rate of asymptomatic excretion. Oral administration of Acyclovir effectively suppresses recurrent genital herpes. Daily administration of Acyclovir reduces the recurrence rate by up to 80%, and 25-30% of patients have no further recurrence while taking the drug.
GEOGRAPHIC ANALYSIS
North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%. In North America, the US is the key revenue contributor mainly due to an increase in the demand for genital herpes drugs reflecting the growing awareness of various antiviral drugs and their benefits against different STIs, including genital herpes. Europe is the second-largest regional market and is witnessing steady growth owing to increasing acceptance of both branded and OTC antiviral drugs for treating genital herpes. However, APAC is likely to see faster growth than all other regions. Around 1 in every ten people in APAC are infected with HSV-2, which majorly causes genital herpes. The APAC region is witnessing high demand for off-label, generic, and OTC drugs for treating genital herpes. The region has many regional and local vendors offering generic and OTC antiviral drugs, which are majorly used for treating genital herpes.
SNAPSHOT
The global genital herpes treatment market was valued at around USD 2.3 billion in 2021 and is expected to reach around USD 2.9 billion by 2027, growing at a CAGR of around 3.76%.
The following factors are likely to contribute to the growth of the global genital herpes treatment market:
- Growing Research & Development on Genital Herpes Vaccine Candidates
- Increasing Awareness & information Regarding Sexual Transmitted Infections
- High Demand for Topical Drugs for Genital Herpes Treatment
- Increasing Purchase of Genital Herpes Therapeutics Through Online Pharmacies
Base Year: 2021
Forecast Year: 2022-2027
The study considers a detailed scenario of the present global genital herpes treatment market and its market dynamics for 2022−2027. It covers a detailed overview of several industry growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Key Vendors
- GlaxoSmithKline
- Business Overview
- Product Offerings
- Key Strengths
- Key Strategies
- Key Opportunities
- Glenmark pharmaceuticals
- Viatris
- Novartis
- Teva Pharmaceuticals
- Bausch Health Companies
Other Prominent Vendors
- Reddy's Laboratories
- Business Overview
- Product Offerings
- Cipla
- Pfizer
- Eli Lilly & Company
- Avet Pharmaceuticals
- Aurobindo Pharma
- Centurion Remedies
- Abbott
- Macleods Pharmaceuticals
- FDC
- Hetero
- Zydus Group
- Torrent Pharma
- Finecure Pharmaceuticals
- ADLEY FORMULATIONS
- Medico Remedies
- Zeelab Pharmacy
Segmentation by Drug Type
- Acyclovir
- Valacyclovir
- Famciclovir
- Other Drugs
Segmentation by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Segmentation by Virus Type
- HSV-2
- HSV-1
Segmentation by Route of Administration:
- Oral
- Topical
- Injection
Segmentation by Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Turkey
- Saudi Arabia
Frequently Asked Questions
HOW BIG IS THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHAT IS THE GROWTH RATE OF THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHO ARE THE KEY PLAYERS IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHAT ARE THE LATEST TRENDS & OPPORTUNITIES IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHICH REGION HOLDS THE LARGEST SHARE IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
LIST OF EXHIBITS
EXHIBIT 1 GLOBAL GENITAL HERPES TREATMENT MARKET SEGMENTATION
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 GLOBAL PREVALENCE OF HSV INFECTIONS 2016
EXHIBIT 4 IMPACT OF R&D OF GENITAL HERPES VACCINE CANDIDATES
EXHIBIT 5 IMPACT OF RISE IN GENITAL HERPES CASES IN LGBTQ+ COMMUNITY
EXHIBIT 6 IMPACT OF MARKET GROWTH POTENTIAL IN LOW-MIDDLE-INCOME COUNTRIES
EXHIBIT 7 IMPACT OF INCREASED ONLINE PURCHASE OF GENITAL HERPES THERAPEUTICS
EXHIBIT 8 IMPACT OF INCREASED BURDEN OF STDS
EXHIBIT 9 HSV-2 INFECTION BY SEX (MILLION)
EXHIBIT 10 IMPACT OF AWARENESS OF STIS
EXHIBIT 11 IMPACT OF DEMAND FOR TOPICAL GENITAL HERPES TREATMENT DRUGS
EXHIBIT 12 ADVANTAGES OF TOPICAL DRUG FORMULATIONS
EXHIBIT 13 IMPACT OF SOCIAL STIGMA ASSOCIATED WITH STDS
EXHIBIT 14 IMPACT OF SIDE EFFECTS & ADVERSE REACTIONS TO GENITAL HERPES MEDICATIONS
EXHIBIT 15 COMMON SIDE EFFECTS OF GENITAL HERPES MEDICATIONS
EXHIBIT 16 SEVERE SIDE EFFECTS OF GENITAL HERPES MEDICATIONS
EXHIBIT 17 IMPACT OF LIMITATIONS OF GENITAL HERPES TREATMENT MEDICATIONS
EXHIBIT 18 GLOBAL GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 19 FIVE FORCES ANALYSIS 2021
EXHIBIT 20 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
EXHIBIT 21 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE: INCREMENTAL GROWTH
EXHIBIT 22 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE: ABSOLUTE GROWTH
EXHIBIT 23 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 24 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR 2021–2027 ($ MILLION)
EXHIBIT 25 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 26 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 27 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR 2021–2027 ($ MILLION)
EXHIBIT 28 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 29 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 30 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR 2021–2027 ($ MILLION)
EXHIBIT 31 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 32 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 33 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS 2021–2027 ($ MILLION)
EXHIBIT 34 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 35 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
EXHIBIT 36 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL: INCREMENTAL GROWTH
EXHIBIT 37 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL: ABSOLUTE GROWTH
EXHIBIT 38 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES 2021–2027 ($ MILLION)
EXHIBIT 40 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 41 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES 2021–2027 ($ MILLION)
EXHIBIT 43 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 44 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 45 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES 2021–2027 ($ MILLION)
EXHIBIT 46 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 47 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
EXHIBIT 48 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE: INCREMENTAL GROWTH
EXHIBIT 49 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE: ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL PREVALENCE OF HSV-1 AND HSV-2 2016 (BILLION)
EXHIBIT 51 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2 2021–2027 ($ MILLION)
EXHIBIT 53 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 54 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1 2021–2027 ($ MILLION)
EXHIBIT 56 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 57 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 58 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION: INCREMENTAL GROWTH
EXHIBIT 59 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION: ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 61 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 62 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 63 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 64 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 65 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 66 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 67 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 68 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 69 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 70 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY
EXHIBIT 71 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY: KEY COUNTRIES ($ MILLION)
EXHIBIT 72 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 73 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 74 NORTH AMERICA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
EXHIBIT 75 NORTH AMERICA GENITAL HERPES TREATMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 76 GENITAL HERPES TREATMENT MARKET IN NORTH AMERICA 2021–2027 ($ MILLION)
EXHIBIT 77 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
EXHIBIT 78 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
EXHIBIT 79 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
EXHIBIT 80 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 81 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 82 PREVALENCE & INCIDENCE OF STIS IN US
EXHIBIT 83 US GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 84 CANADA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 85 EUROPE GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
EXHIBIT 86 EUROPE GENITAL HERPES TREATMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 87 EUROPE GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 88 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
EXHIBIT 89 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
EXHIBIT 90 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
EXHIBIT 91 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 92 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 93 GERMANY GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 94 FRANCE GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 95 UK GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 96 ITALY GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 97 SPAIN GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 98 APAC GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
EXHIBIT 99 APAC GENITAL HERPES TREATMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 100 APAC GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 101 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
EXHIBIT 102 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
EXHIBIT 103 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
EXHIBIT 104 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 105 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 106 CHINA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 107 JAPAN GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 108 INDIA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 109 SOUTH KOREA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 110 PRIORITY POPULATIONS FOR FOURTH NATIONAL STI STRATEGY 2018–2022 AUSTRALIA
EXHIBIT 111 AUSTRALIA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 112 LATIN AMERICA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
EXHIBIT 113 LATIN AMERICA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
EXHIBIT 114 LATIN AMERICA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 115 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
EXHIBIT 116 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
EXHIBIT 117 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
EXHIBIT 118 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 119 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 120 BRAZIL GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 121 MEXICO GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 122 ARGENTINA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 123 MEA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
EXHIBIT 124 MEA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
EXHIBIT 125 MEA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 126 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
EXHIBIT 127 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
EXHIBIT 128 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
EXHIBIT 129 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
EXHIBIT 130 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 131 SOUTH AFRICA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 132 TURKEY GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 133 SAUDI ARABIA GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
EXHIBIT 134 GLAXOSMITHKLINE: TOTAL REVENUE 2018–2020 ($ BILLION)
EXHIBIT 135 GLAXOSMITHKLINE: R&D EXPENDITURE 2018–2020 ($ BILLION)
EXHIBIT 136 GLAXOSMITHKLINE: REVENUE BY BUSINESS SEGMENT 2018–2020 ($ BILLION)
EXHIBIT 137 GLAXOSMITHKLINE: REVENUE SHARE BY GEOGRAPHY 2018–2020 ($ BILLION)
EXHIBIT 138 GLENMARK PHARMACEUTICALS: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 139 GLENMARK PHARMACEUTICALS: R&D EXPENSE 2019–2021 ($ MILLION)
EXHIBIT 140 GLENMARK PHARMACEUTICALS: REVENUE SHARE BY GEOGRAPHY 2021 (%)
EXHIBIT 141 VIATRIS: TOTAL REVENUE 2019–2021 ($ BILLION)
EXHIBIT 142 VIATRIS: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 143 VIATRIS: REVENUE SHARE BY GEOGRAPHY 2021 (%)
EXHIBIT 144 NOVARTIS AG: TOTAL REVENUE 2018–2020 ($ BILLION)
EXHIBIT 145 NOVARTIS AG: REVENUE BY BUSINESS DIVISION 2018–2020 ($ BILLION)
EXHIBIT 146 NOVARTIS AG: R&D EXPENDITURE 2018–2020 ($ BILLION)
EXHIBIT 147 TEVA PHARMACEUTICALS: TOTAL REVENUE 2019–2021 ($ BILLION)
EXHIBIT 148 TEVA PHARMACEUTICALS: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 149 TEVA PHARMACEUTICALS: REVENUE SHARE BY BUSINESS SEGMENT 2021 (%)
EXHIBIT 150 BAUSCH HEALTH COMPANIES INC.: TOTAL REVENUE 2019–2020 ($ BILLION)
EXHIBIT 151 BAUSCH HEALTH COMPANIES INC.: R&D EXPENDITURE 2018–2020 ($ MILLION)
EXHIBIT 152 BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY BUSINESS SEGMENT 2021 (%)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015–2021
TABLE 3 HERPES VACCINE PIPELINE CANDIDATES
TABLE 4 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE
TABLE 5 FAMCICLOVIR PRICING DETAILS
TABLE 6 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL
TABLE 7 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE
TABLE 8 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION
TABLE 9 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 10 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 11 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 12 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 13 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 14 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 15 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 16 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 17 AMERICANS’ SELF-IDENTIFIED SEXUAL ORIENTATION
TABLE 18 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 19 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 20 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 21 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 22 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 23 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 24 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 25 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 26 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 27 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 28 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 29 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 30 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 31 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 32 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 33 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 34 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 35 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 36 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 37 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 38 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 39 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 40 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 41 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 42 MEA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 43 MEA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 44 MEA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 45 MEA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 46 MEA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 47 MEA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 48 MEA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 49 MEA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 50 GLAXOSMITHKLINE: MAJOR PRODUCT OFFERINGS
TABLE 51 GLENMARK PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 52 VIATRIS: MAJOR PRODUCT OFFERINGS
TABLE 53 NOVARTIS AG: MAJOR PRODUCT OFFERINGS
TABLE 54 TEVA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 55 BAUSCH HEALTH COMPANIES INC.: MAJOR PRODUCT OFFERINGS
TABLE 56 AVET PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 57 AUROBINDO PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 58 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 59 ADLEY FORMULATIONS: MAJOR PRODUCT OFFERINGS
TABLE 60 CENTURION REMEDIES: MAJOR PRODUCT OFFERINGS
TABLE 61 CIPLA: MAJOR PRODUCT OFFERINGS
TABLE 62 DR. REDDY’S LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 63 ELI LILLY AND COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 64 FDC LIMITED: MAJOR PRODUCT OFFERINGS
TABLE 65 FINECURE PHARMACEUTICALS LIMITED: MAJOR PRODUCT OFFERINGS
TABLE 66 HETERO: MAJOR PRODUCT OFFERINGS
TABLE 67 MACLEODS PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 68 MEDICO REMEDIES LIMITED: MAJOR PRODUCT OFFERINGS
TABLE 69 PFIZER INC.: MAJOR PRODUCT OFFERINGS
TABLE 70 TORRENT PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 71 ZEELAB PHARMACY: MAJOR PRODUCT OFFERINGS
TABLE 72 ZYDUS GROUP: MAJOR PRODUCT OFFERINGS
TABLE 73 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 74 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 75 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 76 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 77 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 78 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 79 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 80 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 81 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 82 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 83 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 ($ MILLION)
TABLE 84 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021–2027 (%)
TABLE 85 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 86 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 87 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 88 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 89 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 90 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 91 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 92 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 93 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 94 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 95 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 ($ MILLION)
TABLE 96 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021–2027 (%)
TABLE 97 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 98 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 99 NORTH AMERICA HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 100 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 101 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 102 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 103 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 104 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 105 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 106 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 107 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 ($ MILLION)
TABLE 108 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021–2027 (%)
TABLE 109 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 110 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 111 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 112 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 113 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 114 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021202–7 (%)
TABLE 115 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 116 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 117 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 118 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 119 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 ($ MILLION)
TABLE 120 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021–2027 (%)
TABLE 121 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 122 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 123 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR 2021–2027 ($ MILLION)
TABLE 124 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR 2021–2027 (%)
TABLE 125 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR 2021–2027 ($ MILLION)
TABLE 126 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR 2021–2027 (%)
TABLE 127 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR 2021–2027 ($ MILLION)
TABLE 128 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR 2021–2027 (%)
TABLE 129 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS 2021–2027 ($ MILLION)
TABLE 130 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS 2021–2027 (%)
TABLE 131 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES 2021–2027 ($ MILLION)
TABLE 132 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES 2021–2027 (%)
TABLE 133 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES 2021–2027 ($ MILLION)
TABLE 134 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES 2021–2027 (%)
TABLE 135 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES 2021–2027 ($ MILLION)
TABLE 136 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES 2021–2027 (%)
TABLE 137 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2 2021–2027 ($ MILLION)
TABLE 138 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2 2021–2027 (%)
TABLE 139 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1 2021–2027 ($ MILLION)
TABLE 140 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1 2021–2027 (%)
TABLE 141 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
TABLE 142 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET 2021–2027 (%)
TABLE 143 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
TABLE 144 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET 2021–2027 (%)
TABLE 145 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET 2021–2027 ($ MILLION)
TABLE 146 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET 2021–2027 (%)
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY DRUG TYPE
4.3.2 MARKET SEGMENTATION BY DISTRIBUTION CHANNEL
4.3.3 MARKET SEGMENTATION BY VIRUS TYPE
4.3.4 MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
7.1.1 STI CONTROL HEALTH POLICY AGENDA
7.1.2 GLOBAL PREVALENCE OF HSV INFECTIONS
7.1.3 RISK OF HIV AND GENITAL HERPES AMONG THE LGBTQ+ COMMUNITY
8 MARKET OPPORTUNITIES & TRENDS
8.1 R&D OF GENITAL HERPES VACCINE CANDIDATES
8.2 RISE IN GENITAL HERPES CASES IN LGBTQ+ COMMUNITY
8.3 MARKET GROWTH POTENTIAL IN LOW-MIDDLE-INCOME COUNTRIES
8.4 INCREASED ONLINE PURCHASE OF GENITAL HERPES THERAPEUTICS
9 MARKET GROWTH ENABLERS
9.1 INCREASED BURDEN OF STDS
9.2 AWARENESS OF STIS
9.3 DEMAND FOR TOPICAL GENITAL HERPES TREATMENT DRUGS
10 MARKET RESTRAINTS
10.1 SOCIAL STIGMA ASSOCIATED WITH STDS
10.2 SIDE EFFECTS & ADVERSE REACTIONS TO GENITAL HERPES MEDICATIONS
10.2.1 RISKS ASSOCIATED WITH VALACYCLOVIR
10.3 LIMITATIONS OF GENITAL HERPES TREATMENT MEDICATIONS
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 DRUG TYPE
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 ACYCLOVIR
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 ACYCLOVIR: GEOGRAPHY SEGMENTATION
12.4 VALACYCLOVIR
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 VALACYCLOVIR: GEOGRAPHY SEGMENTATION
12.5 FAMCICLOVIR
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 FAMCICLOVIR: GEOGRAPHY SEGMENTATION
12.6 OTHER DRUGS
12.6.1 MARKET OVERVIEW
12.6.2 MARKET SIZE & FORECAST
12.6.3 OTHER DRUGS: GEOGRAPHY SEGMENTATION
13 DISTRIBUTION CHANNEL
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 RETAIL PHARMACIES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 RETAIL PHARMACIES: GEOGRAPHY SEGMENTATION
13.4 HOSPITAL PHARMACIES
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 HOSPITAL PHARMACIES: GEOGRAPHY SEGMENTATION
13.5 ONLINE PHARMACIES
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 ONLINE PHARMACIES: GEOGRAPHY SEGMENTATION
14 VIRUS TYPE
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 HSV-2
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 HSV-2: GEOGRAPHY SEGMENTATION
14.4 HSV-1
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 HSV-1: GEOGRAPHY SEGMENTATION
15 ROUTE OF ADMINISTRATION
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 ORAL
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 ORAL: GEOGRAPHY SEGMENTATION
15.4 TOPICAL
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 TOPICAL: GEOGRAPHY SEGMENTATION
15.5 INJECTION
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 INJECTION: GEOGRAPHY SEGMENTATION
16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW
17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.2.1 NORTH AMERICA: DRUG TYPE SEGMENTATION
17.2.2 NORTH AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
17.2.3 NORTH AMERICA: VIRUS TYPE SEGMENTATION
17.2.4 NORTH AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
17.3 KEY COUNTRIES
17.3.1 US: MARKET SIZE & FORECAST
17.3.2 CANADA: MARKET SIZE & FORECAST
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 EUROPE: DRUG TYPE SEGMENTATION
18.2.2 EUROPE: DISTRIBUTION CHANNEL SEGMENTATION
18.2.3 EUROPE: VIRUS TYPE SEGMENTATION
18.2.4 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION
18.3 KEY COUNTRIES
18.3.1 GERMANY: MARKET SIZE & FORECAST
18.3.2 FRANCE: MARKET SIZE & FORECAST
18.3.3 UK: MARKET SIZE & FORECAST
18.3.4 ITALY: MARKET SIZE & FORECAST
18.3.5 SPAIN: MARKET SIZE & FORECAST
19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 APAC: DRUG TYPE SEGMENTATION
19.2.2 APAC: DISTRIBUTION CHANNEL SEGMENTATION
19.2.3 APAC: VIRUS TYPE SEGMENTATION
19.2.4 APAC: ROUTE OF ADMINISTRATION SEGMENTATION
19.3 KEY COUNTRIES
19.3.1 CHINA: MARKET SIZE & FORECAST
19.3.2 JAPAN: MARKET SIZE & FORECAST
19.3.3 INDIA: MARKET SIZE & FORECAST
19.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
19.3.5 AUSTRALIA: MARKET SIZE & FORECAST
20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 LATIN AMERICA: DRUG TYPE SEGMENTATION
20.2.2 LATIN AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
20.2.3 LATIN AMERICA: VIRUS TYPE SEGMENTATION
20.2.4 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
20.3 KEY COUNTRIES
20.3.1 BRAZIL: MARKET SIZE & FORECAST
20.3.2 MEXICO: MARKET SIZE & FORECAST
20.3.3 ARGENTINA: MARKET SIZE & FORECAST
21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 MEA: DRUG TYPE SEGMENTATION
21.2.2 MEA: DISTRIBUTION CHANNEL SEGMENTATION
21.2.3 MEA: VIRUS TYPE SEGMENTATION
21.2.4 MEA: ROUTE OF ADMINISTRATION SEGMENTATION
21.3 KEY COUNTRIES
21.3.1 SOUTH AFRICA: MARKET SIZE & FORECAST
21.3.2 TURKEY: MARKET SIZE & FORECAST
21.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST
22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
23 KEY COMPANY PROFILES
23.1 GLAXOSMITHKLINE
23.1.1 BUSINESS OVERVIEW
23.1.2 GLAXOSMITHKLINE IN GLOBAL GENITAL HERPES TREATMENT MARKET
23.1.3 PRODUCT OFFERINGS
23.1.4 KEY STRATEGIES
23.1.5 KEY STRENGTHS
23.1.6 KEY OPPORTUNITIES
23.2 GLENMARK PHARMACEUTICALS
23.2.1 BUSINESS OVERVIEW
23.2.2 GLENMARK PHARMACEUTICALS IN GLOBAL GENITAL HERPES TREATMENT MARKET
23.2.3 PRODUCT OFFERINGS
23.2.4 KEY STRATEGIES
23.2.5 KEY STRENGTHS
23.2.6 KEY OPPORTUNITIES
23.3 VIATRIS
23.3.1 BUSINESS OVERVIEW
23.3.2 VIATRIS IN GLOBAL GENITAL HERPES TREATMENT MARKET
23.3.3 PRODUCT OFFERINGS
23.3.4 KEY STRATEGIES
23.3.5 KEY STRENGTHS
23.3.6 KEY OPPORTUNITY
23.4 NOVARTIS AG
23.4.1 BUSINESS OVERVIEW
23.4.2 NOVARTIS AG IN GLOBAL GENITAL HERPES TREATMENT MARKET
23.4.3 PRODUCT OFFERINGS
23.4.4 KEY STRATEGIES
23.4.5 KEY STRENGTHS
23.4.6 KEY OPPORTUNITIES
23.5 TEVA PHARMACEUTICALS
23.5.1 BUSINESS OVERVIEW
23.5.2 TEVA PHARMACEUTICALS IN GLOBAL GENITAL HERPES TREATMENT MARKET
23.5.3 PRODUCT OFFERINGS
23.5.4 KEY STRATEGIES
23.5.5 KEY STRENGTHS
23.5.6 KEY OPPORTUNITIES
23.6 BAUSCH HEALTH COMPANIES INC.
23.6.1 BUSINESS OVERVIEW
23.6.2 BAUSCH HEALTH COMPANIES INC. IN GLOBAL GENITAL HERPES TREATMENT MARKET
23.6.3 PRODUCT OFFERINGS
23.6.4 KEY STRATEGIES
23.6.5 KEY STRENGTHS
23.6.6 KEY OPPORTUNITIES
24 OTHER PROMINENT VENDORS
24.1 AVET PHARMACEUTICALS
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.2 AUROBINDO PHARMA
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.3 ABBOTT
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.4 ADLEY FORMULATIONS
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.5 CENTURION REMEDIES
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.6 CIPLA
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.7 DR. REDDY’S LABORATORIES
24.7.1 BUSINESS OVERVIEW
24.7.2 PRODUCT OFFERINGS
24.8 ELI LILLY AND COMPANY
24.8.1 BUSINESS OVERVIEW
24.8.2 PRODUCT OFFERINGS
24.9 FDC LIMITED
24.9.1 BUSINESS OVERVIEW
24.9.2 PRODUCT OFFERINGS
24.10 FINECURE PHARMACEUTICALS LIMITED
24.10.1 BUSINESS OVERVIEW
24.10.2 PRODUCT OFFERINGS
24.11 HETERO
24.11.1 BUSINESS OVERVIEW
24.11.2 PRODUCT OFFERINGS
24.12 MACLEODS PHARMACEUTICALS
24.12.1 BUSINESS OVERVIEW
24.12.2 PRODUCT OFFERINGS
24.13 MEDICO REMEDIES LIMITED
24.13.1 BUSINESS OVERVIEW
24.13.2 PRODUCT OFFERINGS
24.14 PFIZER INC.
24.14.1 BUSINESS OVERVIEW
24.14.2 PRODUCT OFFERINGS
24.15 TORRENT PHARMA
24.15.1 BUSINESS OVERVIEW
24.15.2 PRODUCT OFFERINGS
24.16 ZEELAB PHARMACY
24.16.1 BUSINESS OVERVIEW
24.16.2 PRODUCT OFFERINGS
24.17 ZYDUS GROUP
24.17.1 BUSINESS OVERVIEW
24.17.2 PRODUCT OFFERINGS
25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS
26 QUANTITATIVE SUMMARY
26.1 DRUG TYPE
26.1.1 NORTH AMERICA: DRUG TYPE SEGMENTATION
26.1.2 EUROPE: DRUG TYPE SEGMENTATION
26.1.3 APAC: DRUG TYPE SEGMENTATION
26.1.4 LATIN AMERICA: DRUG TYPE SEGMENTATION
26.1.5 MIDDLE EAST & AFRICA: DRUG TYPE SEGMENTATION
26.2 DISTRIBUTION CHANNEL
26.2.1 NORTH AMERICA: DISTRIBUTION CHANNEL
26.2.2 EUROPE: DISTRIBUTION CHANNEL
26.2.3 APAC: DISTRIBUTION CHANNEL
26.2.4 LATIN AMERICA: DISTRIBUTION CHANNEL
26.2.5 MIDDLE EAST & AFRICA: DISTRIBUTION CHANNEL
26.3 VIRUS TYPE
26.3.1 NORTH AMERICA: VIRUS TYPE SEGMENTATION
26.3.2 EUROPE: VIRUS TYPE SEGMENTATION
26.3.3 APAC: VIRUS TYPE SEGMENTATION
26.3.4 LATIN AMERICA: VIRUS TYPE SEGMENTATION
26.3.5 MIDDLE EAST & AFRICA: VIRUS TYPE SEGMENTATION
26.4 ROUTE OF ADMINISTRATION
26.4.1 NORTH AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
26.4.2 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION
26.4.3 APAC: ROUTE OF ADMINISTRATION SEGMENTATION
26.4.4 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
26.4.5 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTRATION SEGMENTATION
26.5 GEOGRAPHY
26.5.1 ACYCLOVIR: GEOGRAPHY SEGMENTATION
26.5.2 VALACYCLOVIR: GEOGRAPHY SEGMENTATION
26.5.3 FAMCICLOVIR: GEOGRAPHY SEGMENTATION
26.5.4 OTHER DRUGS: GEOGRAPHY SEGMENTATION
26.5.5 RETAIL PHARMACIES: GEOGRAPHY SEGMENTATION
26.5.6 HOSPITAL PHARMACIES: GEOGRAPHY SEGMENTATION
26.5.7 ONLINE PHARMACIES: GEOGRAPHY SEGMENTATION
26.5.8 HSV-2: GEOGRAPHY SEGMENTATION
26.5.9 HSV-1: GEOGRAPHY SEGMENTATION
26.5.10 ORAL: GEOGRAPHY SEGMENTATION
26.5.11 TOPICAL: GEOGRAPHY SEGMENTATION
26.5.12 INJECTION: GEOGRAPHY SEGMENTATION
27 APPENDIX
27.1 ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
HOW BIG IS THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHAT IS THE GROWTH RATE OF THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHO ARE THE KEY PLAYERS IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHAT ARE THE LATEST TRENDS & OPPORTUNITIES IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
WHICH REGION HOLDS THE LARGEST SHARE IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
Other RELATED Reports
